Solid Biosciences

SLDB · NASDAQ

$6.40+$0.48 (+8.11%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $5.92

SLDB analyst rating

BuyConsensus of 13 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy13
Hold0
Underperform0
Sell0

12-month price target · 16 analysts

Average $19.30 (+201.6% upside)

Low: $14.14
Now: $6.40
High: $27.30

Upgrades and downgrades

The latest rating actions, newest first

SLDB analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 15, 2026	Initiates	Buy	$20.00	69%
RBC Capital	Sep 16, 2026	Initiates	Outperform	$18.00	44%
HC Wainwright & Co.	Sep 14, 2026	Maintains	Buy	$25.00	47%
Cantor Fitzgerald	Aug 27, 2026	Maintains	Overweight	$16.00 → $26.00	41%
Truist Securities	Aug 21, 2026	Maintains	Buy	$16.00 → $20.00	36%
HC Wainwright & Co.	Jun 3, 2026	Maintains	Buy	$20.00 → $25.00	47%
Wedbush	May 18, 2026	Maintains	Outperform	$16.00	40%
Wedbush	May 13, 2026	Maintains	Outperform	$17.00 → $16.00	40%
Piper Sandler	May 13, 2026	Maintains	Overweight	$17.00 → $18.00	40%
JP Morgan	Mar 25, 2026	Maintains	Overweight	$11.00 → $12.00	48%

The case for and against

Updated Oct 14, 2026

Bull case

Solid Biosciences is attractive because its SGT-003 DMD program shows a differentiated profile built on higher muscle targeting, robust microdystrophin and DAPC biomarker expression, and no reported drug-induced liver injury across 53 patients, while using a simpler steroid-only prophylaxis than competing gene therapies. Its outlook is further strengthened by a large, underserved DMD market where SRPT generates about $2b in revenue, yet SLDB may avoid the safety setbacks that have slowed commercial adoption and pressured competitor sentiment. The company also has additional upside from SGT-212 and other early pipeline assets, and the upcoming YE26/early-27 functional readout is the key catalyst that could validate biomarker-to-function translation and support meaningful re-rating potential.

Bear case

Solid Biosciences is a clinical-stage gene therapy company whose value depends heavily on unproven programs in DMD, FA, and CPVT, and the excerpts highlight that failure of these assets could leave the platform worth $0 per share. Its outlook is weakened by substantial clinical and regulatory risk, including questions over microdystrophin-based validation, potential safety signals such as hepatotoxicity or immune-mediated adverse events, and the possibility of a clinical hold as higher-risk patients are enrolled. Financially, the company’s ~$236 million cash, cash equivalents, investments, and available-for-sale securities as of September 30, 2025 may not be sufficient to fund commercialization and development without additional partnerships or financings, while intense competition could compress any eventual market opportunity.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.